Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for adults with cutaneous squamous cell carcinoma (CSCC) – a form of skin cancer. LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI. Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Includes Libtayo side effects, interactions and indications. The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease. Use in Cancer Cemiplimab-rwlc is approved to treat adults with: Basal cell carcinoma (BCC) (a type of skin cancer). It is used in patients whose cancer has spread after treatment with hedgehog pathway inhibitor therapy or who cannot receive hedgehog pathway inhibitor therapy. Cutaneous squamous cell carcinoma (a type of skin cancer). The FDA has approved Libtayo as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma. This article is about Cemiplimab-rwlc (Libtayo), its uses, side effects, dosage, and what to expect during treatment. Libtayo is an immunotherapy drug approved for certain skin and lung cancers. Learn how it works, what conditions it treats, and what to expect during treatment. Learn about side effects, uses, and more for Libtayo (cemiplimab-rwlc), which is a prescription drug that treats certain kinds of skin and lung cancer in adults. What is LIBTAYO? LIBTAYO (Lib-TIE-oh) is a prescription medicine used to treat people with a type of skin cancer called basal cell carcinoma that cannot be removed by surgery (locally advanced BCC) and have received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with an HHI.